This reagent is required to perform all testing which provide healthcare providers with critical information in the detection/management of allergic reactions for SAN antonio market and 153 other…
Ended Awarded
- Contract number
- HT009025FG0830122
- Awardee
-
Phadia US Inc. UEI DK4EVCWUNUM4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $20,580
Award facts
- Contract value 100% obligated
- $20,580.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Portage, MI 49002, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $20,580 firm-fixed-price Blanket Purchase Agreement (BPA) call to Phadia US Inc.'s Immunodiagnostics Division on August 26, 2025, with completion targeted for September 30, 2025. This contract procures allergen-specific immunoglobulin E (IgE) reagents essential for allergy testing and management across the San Antonio military treatment facility and 153 additional military healthcare installations. The reagent supply supports critical diagnostic capabilities that enable healthcare providers to detect and manage allergic reactions in military beneficiaries. No set-aside designation was utilized in this open market procurement.
Phadia US Inc., a Thermo Fisher Scientific subsidiary specializing in advanced allergy and autoimmune diagnostic solutions, has established itself as a key provider of immunodiagnostic equipment and supplies to federal defense agencies. The company holds significant Indefinite Delivery/Indefinite Quantity vehicles with the Air Force Air Education and Training Command, valued at $13.8 million each, which facilitate broader procurement of IMMUNOCAP SYSTEM analyzers and related diagnostic equipment across military medical facilities nationwide. This BPA call represents a continuation of Phadia's strategic role in supporting military medical diagnostic capabilities through specialized testing reagents and materials.
Description
This reagent is required to perform all testing which provide healthcare providers with critical information in the detection/management of allergic reactions for SAN antonio market and 153 other military treatment facilities.
Quick answers
Who was awarded contract HT009025FG0830122?
HT009025FG0830122 was awarded to Phadia US Inc. by Defense Health Agency (Department of Defense) on August 26, 2025.
How much is contract HT009025FG0830122 worth?
The government has obligated $20,580 on HT009025FG0830122.
Is contract HT009025FG0830122 an order under another contract?
Yes. HT009025FG0830122 is a BPA call under FA301624A0046, a blanket purchase agreement.
Was contract HT009025FG0830122 competed?
The extent of competition for HT009025FG0830122 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award